Evaxion Showcases EVX-01 Data at the Prestigious AACR Meeting
Exciting Presentation at AACR Annual Meeting
Evaxion Biotech A/S (NASDAQ: EVAX) is set to make waves at the American Association for Cancer Research (AACR) Annual Meeting. The company is eager to share new findings regarding its personalized cancer vaccine EVX-01, specifically designed for advanced melanoma treatment. The event, scheduled for late April, promises to spotlight significant advancements in cancer vaccine development driven by artificial intelligence.
New Biomarker Insights
Diving into the details, Evaxion will unveil new biomarker and immune response data from its ongoing phase 2 clinical trial. This presentation aims to enhance the existing strong clinical data related to EVX-01, further solidifying its potential in cancer therapy.
Clinical Trial Progress and Insights
The phase 2 trial has previously shown promising one-year interim clinical data, suggesting that EVX-01 is on the right path. With the anticipated readout of two-year clinical efficacy data projected for the latter half of the year 2025, the trial continues to make strides. Notably, the study has recently been extended to assess the vaccine's full potential over an additional third year, paving the way for an even more thorough evaluation.
Acknowledgment from AACR
Birgitte Rønø, Chief Scientific Officer of Evaxion, expressed pride in being selected by the AACR’s scientific committee to present at this esteemed meeting. The opportunity to present these important findings alongside influential members of the melanoma research community underscores the clinical significance of the EVX-01 program.
Presentation Details
The presentation will detail:
- Abstract Title: T-cell immunogenicity and biomarker profiling in advanced melanoma patients receiving the personalized vaccine EVX-01 in combination with pembrolizumab.
- Abstract #: 4538
- Poster #: 9
- Session Category: Immune responses to therapies including chemotherapy and radiotherapy
- Location: Poster section 28
- Date/Time: April 29, at 9 am-12 pm CST
- Presenter: Mads Lausen Nielsen, PhD, Project Manager at Evaxion
About EVX-01
EVX-01 is not just any vaccine. It represents a personalized peptide-based approach intended for first-line treatments of various advanced solid tumors. Tailored using Evaxion's innovative AI-Immunology™ platform, each vaccine is crafted to address the unique tumor profiles and immune characteristics inherent to each patient, enhancing the potential for a targeted immune response.
Clinical Success and Potential
In clinical assessments, EVX-01 has showcased impressive overall response rates of 69% and 67% among advanced melanoma patients. Such results underline the effectiveness of the AI-Immunology™ predictions, emphasizing the sophisticated technology driving Evaxion's breakthroughs.
Contact Information
For those interested in learning more about Evaxion’s groundbreaking work and upcoming presentations, feel free to reach out:
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
About Evaxion Biotech A/S
Evaxion Biotech A/S stands as a trailblazer in the TechBio sector, thriving on its cutting-edge AI platform, AI-Immunology™. This proprietary technology empowers Evaxion to decode the complexities of the human immune system, setting the stage for breakthrough immunotherapies aimed at cancer, bacterial diseases, and viral infections. Through its advanced pipeline of personalized vaccines and innovative approaches to infectious diseases, Evaxion is committed to revolutionizing treatment options and improving patient outcomes globally.
Frequently Asked Questions
What data will Evaxion present at the AACR Annual Meeting?
Evaxion will present new biomarker and immune response data from the ongoing phase 2 trial of EVX-01.
What is EVX-01 developed for?
EVX-01 is a personalized cancer vaccine aimed at treating advanced melanoma.
When is the fast-approaching presentation?
The presentation will occur on April 29, 2025, from 9 am to 12 pm CST at the AACR Annual Meeting.
What are the significant outcomes from the phase 2 trial thus far?
The trial has reported strong interim clinical data, with projected two-year efficacy results expected in the second half of 2025.
How does Evaxion utilize AI in their research?
Evaxion employs its AI-Immunology™ platform to tailor vaccines based on individual tumor profiles and immune characteristics, optimizing treatment effectiveness.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.